Crinetics Pharmaceuticals, Inc.: current liabilities
Current liabilities for Crinetics Pharmaceuticals, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Crinetics Pharmaceuticals, Inc. financial histories
What this measure means
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
Exact concept: us-gaap:LiabilitiesCurrent. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2017-12-31 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 85,072,000 | USD | 2026-02-26 | 10-K · 0001658247-26-000012 |
| At date | 2024-12-31 | 59,684,000 | USD | 2026-02-26 | 10-K · 0001658247-26-000012 |
| At date | 2023-12-31 | 43,942,000 | USD | 2025-02-27 | 10-K · 0000950170-25-029050 |
| At date | 2022-12-31 | 27,723,000 | USD | 2024-02-28 | 10-K · 0000950170-24-022108 |
| At date | 2021-12-31 | 15,995,000 | USD | 2023-02-28 | 10-K · 0000950170-23-005132 |
| At date | 2020-12-31 | 10,489,000 | USD | 2022-03-30 | 10-K · 0000950170-22-005050 |
| At date | 2019-12-31 | 8,340,000 | USD | 2021-03-30 | 10-K · 0001564590-21-016719 |
| At date | 2018-12-31 | 7,925,000 | USD | 2020-03-09 | 10-K · 0001564590-20-009365 |
| At date | 2017-12-31 | 897,000 | USD | 2019-03-13 | 10-K · 0001564590-19-007561 |
Related financial histories
- Crinetics Pharmaceuticals, Inc.: total assets
- Crinetics Pharmaceuticals, Inc.: total liabilities
- Crinetics Pharmaceuticals, Inc.: stockholders equity
- Crinetics Pharmaceuticals, Inc.: cash and cash equivalents
- Crinetics Pharmaceuticals, Inc.: net income or loss
- Crinetics Pharmaceuticals, Inc.: operating cash flow
- Crinetics Pharmaceuticals, Inc.: capital expenditure payments
- Crinetics Pharmaceuticals, Inc.: revenue
- Crinetics Pharmaceuticals, Inc.: contract revenue excluding tax
- Crinetics Pharmaceuticals, Inc.: financing cash flow
- Crinetics Pharmaceuticals, Inc.: investing cash flow
- Crinetics Pharmaceuticals, Inc.: retained earnings or deficit
- Crinetics Pharmaceuticals, Inc.: basic weighted-average shares
- Crinetics Pharmaceuticals, Inc.: diluted weighted-average shares
- Crinetics Pharmaceuticals, Inc.: basic earnings per share
- Crinetics Pharmaceuticals, Inc.: diluted earnings per share
- Crinetics Pharmaceuticals, Inc.: income tax expense or benefit
- Crinetics Pharmaceuticals, Inc.: net property, plant and equipment
- Crinetics Pharmaceuticals, Inc.: share-based compensation expense
- Crinetics Pharmaceuticals, Inc.: operating income or loss
- Crinetics Pharmaceuticals, Inc.: current assets
- Crinetics Pharmaceuticals, Inc.: current accounts payable
- Crinetics Pharmaceuticals, Inc.: operating expenses
- Crinetics Pharmaceuticals, Inc.: cost of revenue
- Crinetics Pharmaceuticals, Inc.: selling, general and administrative expense
- Crinetics Pharmaceuticals, Inc.: research and development expense
Inspect the source
- Entity
- Crinetics Pharmaceuticals, Inc. / CIK 0001658247
- Captured
- 2026-09-21T17:23:51.225Z
- SEC response SHA-256
6f03f5909991c046d183f31ea1f13fb33087a842bd0a4d5e01b89ea2e3870aa4
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001658247.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))